Ads
related to: Dupixent- Pricing And Insurance
Check Copay Eligibility
Learn About Payment Options
- FAQs
Find Answers To Your Questions
& Understand Treatment Now
- Injection Support Center
Get Help With Taking DUPIXENT®
View Injection Resources Now
- Patient Support
Access DUPIXENT MyWay®
Get Patient Journey Support Today
- Pricing And Insurance
Search results
ASLAN expands research on atopic dermatitis treatment By Investing.com
Investing.com· 3 days agoASLAN Pharmaceuticals (NASDAQ:ASLN), a clinical-stage biopharmaceutical company, has announced a new...
Regeneron (REGN) Reports Q1 Earnings: What Key Metrics Have to Say
Zacks· 4 days agoAlthough the revenue and EPS for Regeneron (REGN) give a sense of how its business performed in the quarter ended March 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Kymera Therapeutics, Inc. (NASDAQ:KYMR) Q1 2024 Earnings Call Transcript
Insider Monkey via Yahoo Finance· 2 days agoKymera Therapeutics, Inc. (NASDAQ:KYMR) Q1 2024 Earnings Call Transcript May 3, 2024 Kymera...
Kymera (KYMR) Q1 Loss Narrower Than Expected, Pipeline in Focus
Zacks via Yahoo Finance· 3 days agoKymera (KYMR) reports a narrower-than-expected loss in the first quarter. The company expects the...
Countdown to Regeneron (REGN) Q1 Earnings: A Look at Estimates Beyond Revenue and EPS
Zacks· 7 days agoFree Report) is expected to reveal quarterly earnings of $10.14 per share, indicating an increase of 0.5% compared to the year-ago period. Analysts forecast revenues of $3.19 billion, representing ...
Earnings call: Kymera Therapeutics reports progress in drug development By Investing.com
Investing.com· 3 days agoKymera Therapeutics, during their first quarter 2024 earnings call, provided a comprehensive update...
Stopping the sniffles: Don't let nasal polyps steal your scent-sibility
La Crosse Tribune· 2 days ago“Nasal polyps are soft, noncancerous growths on the nasal passages or sinus linings that can cause...
Small Business - Austin Daily Herald | Austin Daily Herald
Austin Daily Herald· 4 days agoFirst quarter 2024 revenues decreased 1% to $3.15 billion versus first quarter 2023; excluding RonapreveTM(a)(b), revenues increased 7%First quarter 2024 Dupixent® global net sales (recorded by Sanofi) increased 24% to $3.08 billion versus first
Ads
related to: Dupixent